Study guide
5.2 Radiopharmaceutical Kit Preparation
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
5.2 Radiopharmaceutical Kit Preparation
Key Takeaways Explain This Topic AI
Cold kits contain nonradioactive ligands and a reducing agent (usually stannous ion); Tc-99m pertechnetate is added to form the labeled radiopharmaceutical
Strict activity and volume limits on the package insert protect labeling efficiency, purity, and (for MAA) particle number
Patient dose calculations use assayed kit concentration, decay correction, and ordered activity—never guess volume without math
MAA particle size is typically in the 10–90 μm range; adult doses use a controlled particle count, reduced for children and pulmonary hypertension
Store unreconstituted kits per labeled temperature; after reconstitution, observe manufacturer expiration (often hours), temperature, and light protection
Last updated: August 2026
A cold kit is a sterile, nonradioactive vial with ligand , usually a reducing agent , and stabilizers. Adding Tc-99m sodium pertechnetate creates the radiopharmaceutical. Domain III expects correct reconstitution, activity/volume limits, patient-dose math, and special rules for MAA .
Cold Kit Reconstitution Workflow
Always follow the package insert :
Verify kit ID, lot, unreconstituted expiration , and storage history.
Assay Tc-99m pertechnetate ; confirm Mo-99 and Al³⁺ QC are acceptable.
Aseptically add the correct activity in the correct volume (some kits need diluent or a specific order of addition).
Mix as directed; complete any required incubation or heating (e.g., certain MAG3, sestamibi, or sulfur colloid protocols).
Assay the vial, calculate concentration , and label name, activity, concentration, time, expiration, and lot.
Draw patient doses with a syringe shield , assay each syringe, and document.
Use aseptic technique : sterile needles, swabbed septa, no-touch method, and laminar-flow or equivalent controls when policy/USP <825> practices apply.
Labeling Chemistry (Reduction of Pertechnetate)
Eluate contains pertechnetate , Tc(VII)—chemically unreactive toward most ligands. Kits include stannous ion (Sn²⁺) that reduces technetium so it can complex MDP, DTPA, MIBI, tetrofosmin, mebrofenin, and similar ligands.
- Concept Meaning
- TcO₄⁻ Oxidized Tc(VII); “free tech” if unbound
- Stannous reduction Sn²⁺ lowers Tc oxidation state for ligand binding
- Air / oxidants Reoxidation → free pertechnetate
- Too much Tc or weak Sn²⁺ Incomplete labeling
- HR-Tc Reduced Tc forming colloid instead of the intended complex
Stay inside insert limits; avoid oxidants and unnecessary air; do not use high-Al³⁺ eluate when warned. Some products use ligand exchange , boiling, or pH control—the core idea remains reduce, then bind .
Activity and Volume Limits
Inserts set max/min Tc-99m activity and reconstitution volume :
Too much activity can overwhelm reducing capacity → poor RCP.
Wrong volume changes concentration and dose logistics.
Insufficient Sn²⁺ relative to Tc → free tech or colloids.
Limits apply at preparation ; multi-dose use must stay within post-reconstitution shelf life .
Worked example 1 — Kit limits
Insert: 20–100 mCi in 1–5 mL . Need five ~20 mCi doses → 100 mCi in 5 mL (20 mCi/mL) is within limits. Loading 150 mCi “to save a vial” violates the insert and risks failed QC.
Patient Dose Calculations Concentration (mCi/mL) = Total activity Total volume \text{Concentration (mCi/mL)} = \frac{\text{Total activity}}{\text{Total volume}} Concentration (mCi/mL) = Total volume Total activity V = Ordered activity Concentration V = \frac{\text{Ordered activity}}{\text{Concentration}} V = Concentration Ordered activity
Decay if injection is delayed (Tc-99m T 1 / 2 ≈ 6 h T_{1/2} ≈ 6\ \text{h} T 1/2 ≈ 6 h ): A t = A 0 ( 1 2 ) t / T 1 / 2 A_t = A_0 \left(\frac{1}{2}\right)^{t/T_{1/2}} A t = A 0 ( 2 1 ) t / T 1/2
Worked example 2 — Draw volume
80 mCi in 4 mL → 20 mCi/mL . Order 25 mCi → 1.25 mL . Assay the syringe and adjust if needed.
Worked example 3 — Decay
Syringe 25 mCi at 08:00 ; inject at 11:00 (3 h): A = 25 × ( 1 / 2 ) 3 / 6 = 25 × 1 / 2 ≈ 25 × 0.707 ≈ 17.7 m C i A = 25 \times (1/2)^{3/6} = 25 \times \sqrt{1/2} ≈ 25 \times 0.707 ≈ \mathbf{17.7\ mCi} A = 25 × ( 1/2 ) 3/6 = 25 × 1/2 ≈ 25 × 0.707 ≈ 17.7 mCi
If 25 mCi is required at injection , draw more at 08:00 or redraw later.
Worked example 4 — Units
Order 740 MBq MDP → 740/37 = 20 mCi for calibrator math; document in the unit your facility requires.
MAA: Particle Size and Number
Tc-99m MAA is particulate; aggregates temporarily lodge in pulmonary arterioles/capillaries.
- Parameter Teaching range Why
- Particle size Roughly 10–90 μm Too small → pass lungs; too large → larger-vessel obstruction
- Adult particle number Often ~200,000–700,000 /dose (follow insert) Uniform map without excess blockade
- Pediatrics Reduce particles (and often activity) Smaller vascular bed
- Pulmonary hypertension / R-to-L shunt protocols Reduce particles Limit occlusion / systemic particle risk
Do not inject blood into the MAA vial (clumping); gently resuspend before drawing; never use a 0.22 μm filter that strips particles; reject clumped product. High activity in small volume raises particles per mL —count matters as much as mCi.
Worked example 5 — Particles
Vial: 6 × 10⁶ particles in 6 mL , 30 mCi → 1 × 10⁶ particles/mL and 5 mCi/mL. A 4 mCi adult draw (0.8 mL) ≈ 800,000 particles —may exceed lab ceilings; dilute or prepare lower particle density. Child limited to 100,000 particles → 0.1 mL of that suspension (activity only 0.5 mCi unless a low-density prep is used).
Storage and Expiration
- State Controls
- Unreconstituted kit Labeled fridge or room temp; light protection if stated; freeze only if allowed
- After reconstitution Temp per insert; multi-dose aseptic withdrawals
- Expiration Unreconstituted manufacturer dating; post-reconstitution often ~6–12 h (product-specific)
- Eluate age Some kits prefer fresh eluate
Reject expired kits, failed visual/RCP products, and temperature-abused vials per RSO/pharmacy policy.
Multi-Dose Logistics
Plan kit activity so morning and afternoon lists fit inside both the activity limit and the expiration clock . If the last dose would be drawn after dating, prepare a second kit rather than stretching a marginal vial. Always assay the patient syringe , not only the bulk vial, before administration.
Exam hooks: Sn²⁺ reduces TcO₄⁻; honor activity/volume limits; mCi/mL + decay math; MAA particle number (peds/PHTN); storage/expiration differ before vs after reconstitution.